Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 2/2013

01-02-2013 | Review

Targeted immunotherapy trials for idiopathic inflammatory myopathies

Author: Joerg-Patrick Stübgen

Published in: Journal of Neurology | Issue 2/2013

Login to get access

Abstract

The idiopathic inflammatory myopathies (IIM) are a group of muscle diseases with complex immunopathogenesis that varies between disease subgroups, and possibly between patients within the same subgroup. There exists no universal consensus on optimum management, so that no “standard” therapy has been developed. Treatment-refractive IIM remains a clinical challenge. Progress in the development and application of molecular biology techniques and biological therapeutics are evolving into a new scientific frontier in the management of autoimmune diseases. This review offers an update on those components of the humoral and cellular immunity deemed potential targets for biological therapeutics (monoclonal antibodies and fusion proteins) that have been approved by the US FDA for treatment of immunological disorders. A futuristic approach is envisioned in which each individual will receive targeted therapy tailored to patient-specific immune mechanisms. Risk–benefit and cost analyses should determine whether such targeted therapy is appropriate and feasible for refractive and/or newly diagnosed disease.
Literature
1.
Greenberg SA (2007) Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 69:2008–2019PubMedCrossRef
2.
Dalakas MC (2010) Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 6:129–137PubMedCrossRef
3.
Weihl CC, Pestronk A (2010) Sporadic inclusion body myositis: possible pathogenesis inferred fro biomarkers. Curr Opin Neurol 23:482–484PubMedCrossRef
4.
Gherardi RK (2011) Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 40:e209–e218PubMedCrossRef
5.
Zong M, Lundberg IE (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7:297–306PubMedCrossRef
6.
Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International myositis assessment and clinical studies group (2005) International consensus for the trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615PubMedCrossRef
7.
8.
Dalakas MC (2011) Immunotherapy of inflammatory myopathies: practical approach ad future prospects. Curr Treat Options Neurol 13:311–323PubMedCrossRef
9.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRef
10.
Chérin P (2008) Current therapy for polymyositis and dermatomyositis. Rev Méd Interne 29:9–14PubMed
11.
Hughes RAC, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N (2009) Clinical applications of intravenous immunoglobulin fin neurology. Clin Exp Immunol 158(Suppl):34–42PubMedCrossRef
12.
Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712–716PubMedCrossRef
13.
Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Müller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22–28PubMedCrossRef
14.
15.
16.
Brandåo M, Marinho A (2011) Idiopathic inflammatory myopathies: definition and management of refractory disease. Autoimmun Rev 10:720–724PubMedCrossRef
17.
Dalakas MC (2011) Inflammaory myopathies: management of steroid resistance. Curr Opin Neurol 24:457–462PubMedCrossRef
18.
Hengstman GJ, van den Hoogen FH, van Engelen BG (2009) Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 10:1183–1190PubMedCrossRef
19.
Chatenoud L (2009) Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr Opin Organ Transplant 14:351–356PubMedCrossRef
20.
Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. Brit Med J 312:1215–1218PubMedCrossRef
21.
Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW (2007) The valuable contribution of observational studies to nephrology. Kidney Int 72:671–675PubMedCrossRef
22.
McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C (1999) Interpreting the evidence: choosing between randomised and non-randomised studies. Brit Med J 319:312–315PubMedCrossRef
23.
Vandenbrouke JP (2004) When are observational studies as credible as randomised trials? Lancet 363:1728–1731CrossRef
24.
Kunz R, Oxman AD (1998) The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. Brit Med J 317:1185–1190PubMedCrossRef
25.
MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AM (2000) A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess 4:1–154PubMed
26.
Noordzij M, Deker FW, Zoccali C, Jager KJ (2009) Study designs in clinical research. Nephron Clin Pract 113:c218–c221PubMedCrossRef
27.
Goetz FW, Planas JV, Mackenzie S (2004) Tumor necrosis factors. Dev Comp Immunol 28:287–297CrossRef
28.
MacEwan DJ (2002) TNF receptor subtype signaling: differences and cellular consequences. Cell Signal 14:477–492PubMedCrossRef
29.
Slowik MR, De Luca LG, Fiers W, Pober JS (1993) Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 143:1724–1730PubMed
30.
Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359PubMedCrossRef
31.
Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585–588PubMedCrossRef
32.
Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G (2003) Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berlin) 105:217–224
33.
De Bleecker JL, Meire VI, Declerq W, Van Aken EH (1999) Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9:239–246PubMedCrossRef
34.
Peterson JM, Feeback KD, Baas JH, Pizza FX (2006) Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J Appl Physiol 101:1394–1399PubMedCrossRef
35.
Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC (2008) Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 131:1228–1240PubMedCrossRef
36.
Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD, Shires GT (1986) Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 164:1368–1373PubMedCrossRef
37.
Lee MD, Zentella A, Vine W, Pekala PH, Cerami A (1987) Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 84:2590–2594PubMedCrossRef
38.
Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW (1989) Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 83:1614–1622PubMedCrossRef
39.
Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ, Argiles JM (1993) Tumor necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 323:211–214PubMedCrossRef
40.
Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269–271PubMedCrossRef
41.
Reid MB, Lannergren J, Westerblad H (2002) Respiratory and limb muscle weakness induced by tumor necrosis factor alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 166:479–484PubMedCrossRef
42.
Stübgen JP (2011) Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 258:961–970PubMedCrossRef
43.
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR (2006) Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66(Suppl 1):S123–S124PubMedCrossRef
44.
Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of 8 patients. Ann Rheum Dis 65:1233–1236PubMedCrossRef
45.
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804PubMed
46.
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47:877–880PubMedCrossRef
47.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677PubMedCrossRef
48.
Hengstman GJ, de Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH (2008) Open-label trial of anti-TNF-α in dermatomyositis and polymyositis treated concomitantly with methotrexate. Eur Neurol 59:159–163PubMedCrossRef
49.
Coyle K, Pokrovnichka A, French K, Joe G, Shrader J, Swan L, Cabalar I, Harris-Love M, Plotz P, Miller F, Gourley M (2008) A randomized, double-blind, placebo-controlled trail of infliximab in patients with polymyositis and dermatomyositis. Arthritis Rheum 58(Suppl):S923–S924
50.
The muscle study group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427–436CrossRef
51.
Tyring SK (1995) Interferons: biochemistry and mechanisms of action. Am J Obstet Gynecol 172:1350–1353PubMedCrossRef
52.
Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, Amato AA (2002) Molecular profiles of inflammatory myopathies. Neurology 59:1170–1182PubMedCrossRef
53.
Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ (1999) The nature of the principal type I interferon-producing cells in human blood. Science 284:1835–1837PubMedCrossRef
54.
Feldman D, Goldstein AL, Cox DC, Grimley PM (1988) Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2′,5′ oligoadenylate synthetase induction. Lab Invest 58:584–589PubMed
55.
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA (2005) Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664–678PubMedCrossRef
56.
Gallardo E, de Andres I, Illa I (2001) Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 60:847–855PubMed
57.
Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, Plotz P, Rosen A, Hoffman E, Raben N (2005) Activation of endoplasmic reticulum stress response in autoimmune myositis: a potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52:1824–1835PubMedCrossRef
58.
Pedrol E, Grau JM, Casademont J, Cid MC, Masanés F, Fernandez-Sola J, Urbano-Mårquez A (1995) Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin Neuropathol 14:179–184PubMed
59.
Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM (2007) An interferon signature in peripheral blood in dermatomyositis patients is associated with disease activity. Mol Med 13:59–68PubMedCrossRef
60.
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60:3436–3446PubMedCrossRef
61.
62.
Yao Y, Higgs BW, Richman L, White B, Jallal B (2010) Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN alpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 12(Suppl 1):S6PubMedCrossRef
63.
Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, White B, Lupus interferon skin activity (LISA) study investigators (2011) Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase 1, multicentre, double-blind randomised study. Ann Rheum Dis 70:1905–1911PubMedCrossRef
64.
Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40:865–874PubMedCrossRef
65.
Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE (2007) Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 56:674–687PubMedCrossRef
66.
De Paepe B, Creus KK, De Bleecker JL (2009) Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 21:610–616PubMedCrossRef
67.
Lundberg I, Kratz AK, Alexanderson H, Patarroyo M (2000) Decreased expression of interleukin-1 alpha, interleukin-1 beta and cell adhesion molecules in muscle tissue following corticoid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 43:336–348PubMedCrossRef
68.
Englund P, Nennesmo I, Klareskog L, Lundberg IE (2002) Interleukin-1 alpha expression in capillaries and major histocompatibility complex class 1 expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 46:1044–1055PubMedCrossRef
69.
Baird GS, Montine TJ (2008) Multiple immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med 132:232–238PubMed
70.
Fan J, Wojnar MM, Theodorakis M, Lang CH (1996) Regulation of insulin-like growth factor (IGF)-1 mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 270:R621–R629PubMed
71.
Frost RA, Lang CH (2004) Alteration of somatic function by proinflammatory cytokines. J Anim Sci 82(E Suppl):E100–E109PubMed
72.
Dalakas MC (2008) Molecular links between inflammation and degeneration: lessons on “neuroinflammation” using IBM as a model. Ann Neurol 64:1–3PubMedCrossRef
73.
Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE (2005) Marked expression of IL-1 receptors in cell nuclei and muscle fiber membrane in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Res Ther 7(Suppl):S33CrossRef
74.
Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMedCrossRef
75.
Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis-dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase response. Arthritis Rheum 37:1744–1751PubMedCrossRef
76.
Prieur AM, Drayer A, Roux-Lombard P, Dayer JM (1997) Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis. Clin Exp Rheumatol 15:211–214PubMed
77.
Son K, Tomita Y, Shimizu T, Nishinarita S, Sawada S, Horie T (2000) Abnormal IL-1 antagonist production in patients with polymyositis and dermatomyositis. Intern Med 39:128–135PubMedCrossRef
78.
Dorph C, Dastmalchi M, Alexanderson H, Ottosson C, Lindroos E, Nennesmo I, Lundberg IE (2009) Anakinra in patients with refractory idiopathic inflammatory myopathies. Arthritis Rheum 60(Suppl 10):589
79.
Zong M, Malmstrøm V, Lundberg IE (2011) Anakinra effects on T cells in patients with refractory idiopathic inflammatory myopathies. Ann Rheum Dis 70(Suppl 2):A80–A81CrossRef
80.
Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12:180–190PubMed
81.
Létourneau S, Krieg C, Pantaleo G, Boyman O (2009) IL-2 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 123:758–762PubMedCrossRef
82.
Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 8:3172–3177
83.
Semenzato G, Bambara LM, Biasi D, Frigo A, Vinante F, Zuppini B, Trentin L, Feruglio C, Chilosi M, Pizzolo G (1988) Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 8:447–452PubMedCrossRef
84.
Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV (1991) Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 30:48–53PubMedCrossRef
85.
Manoussakis MN, Germanidis GS, Drosos AA, Moutsopoulos HM (1992) Impaired urinary excretion of soluble IL-2 receptors in patients wit systemic lupus erythematosus and rheumatoid arthritis. Lupus 1:105–109PubMedCrossRef
86.
Wolf RE, Baethge BA (1990) Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 33:1007–1014PubMedCrossRef
87.
Tokano Y, Kanai Y, Hashimoto H, Okumura K, Hirose S (1992) Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis. Ann Rheum Dis 51:781–782PubMedCrossRef
88.
Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29–35PubMed
89.
Kobayashi I, Ono S, Kawamura N, Okano M, Kobayashi K (2001) Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis. Pediatr Int 43:109–111PubMedCrossRef
90.
Samsonov MY, Nassonov EL, Tilz GP, Geht BM, Demel U, Gurkina GT, Shtutman VZ, Guseva AG, Wachter H, Fuchs D (1997) Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Br J Rheumatol 36:656–660PubMedCrossRef
91.
Giorno R, Ringel SP (1986) Analysis of macrophages, activated cells and T cell subsets in inflammatory myopathies using monoclonal antibodies. Pathol Immunopathol Res 5:491–499PubMedCrossRef
92.
Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC (1986) Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 63:450–458PubMed
93.
Esteva-Lorenzo FJ, Janik JE, Fenton RG, Emslie-Smith A, Engel AG, Longo DL (1995) Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 76:1219–1223PubMedCrossRef
94.
Finger DR, Plotz PH, Heywood G (1995) Myositis following treatment with high-dose interleukin-2 for malignancy. J Rheumatol 22:2188PubMed
95.
Fraenkel PG, Rutkove SB, Matheson JK, Fowkes M, Cannon ME, Patti ME, Atkins MB, Gollob JA (2002) Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 25:373–378PubMedCrossRef
96.
Martin R (2012) Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 142:9–14PubMedCrossRef
97.
Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P, Del Tacca M, Mosca F (2004) A risk-benefit assessment of basiliximab in renal transplantation. Drug Saf 27:91–106PubMedCrossRef
98.
Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785–789PubMedCrossRef
99.
Schippling DS, Martin R (2008) Spotlight on anti-CD25: daclizumab in MS. Int MS J 15:94–98PubMed
100.
Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD (2003) Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18:65–75PubMedCrossRef
101.
Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM, Basbuc investigators (2006) Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 23:1435–1442PubMedCrossRef
102.
Becker MO, Brückner C, Scherer HU, Wassermann N, Humrich JY, Hanitsch LG, Schneider U, Kawald A, Hanke K, Burmester GR, Riemekasten G (2011) The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 70:1340–1341PubMedCrossRef
103.
Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional study. Ophthalmology 112:764–770PubMedCrossRef
104.
Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm 15:63–70PubMedCrossRef
105.
Owen CM, Harrison PV (2000) Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 25:195–197PubMedCrossRef
106.
Salim A, Emerson RM, Daiziel KL (2000) Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 143:1121–1122PubMedCrossRef
107.
Kakoulidou M, Pirskanen-Mateli R, Lefvert AK (2008) Treatment of a patient with myasthenia gravis using antibodies against CD25. Acta Neurol Scand 117:211–216PubMedCrossRef
108.
Garcia-Pous M, Hernåndez-Garfella ML, Dîaz-Llopis M (2007) Treatment of chronic orbital myositis with daclizumab. Can J Ophthalmol 42:156–157PubMed
109.
Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6-trans-signalling in chronic inflammation and cancer. Scand J Immunol 63:321–329PubMedCrossRef
110.
Rose-John S, Waetzig GH, Scheiler J, Grotzinger J, Seegert D (2007) The Il-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11:613–624PubMedCrossRef
111.
Kallen KJ (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human disease. Biochim Biophys Acta 1592:323–343PubMedCrossRef
112.
Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73–76PubMedCrossRef
113.
Murakami M, Nishimoto N (2011) The value of blocking IL-6 outside rheumatoid arthritis: current perspective. Curr Opin Rheumatol 23:273–277PubMedCrossRef
114.
Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of interleukin-6 receptor. Ann Rev Pharmacol Toxicol 52:199–219CrossRef
115.
Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF (1998) Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24:73–79PubMedCrossRef
116.
Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N (2000) Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40–CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 164:6593–6600PubMed
117.
Tucci M, Quatraro C, Dammacco F, Silvestris F (2007) Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann NY Acad Sci 1107:184–192PubMedCrossRef
118.
Sugihara T, Sekine C, Nakae T, Kohyama K, Harigal M, Iwakura Y, Matsumoto Y, Miyasaka N, Kohsaka H (2007) A new murine model to define the critical pathogenic and therapeutic mediators of polymyositis. Arthritis Rheum 56:1304–1314PubMedCrossRef
119.
Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60:2505–2512PubMedCrossRef
120.
Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systemic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50:552–562CrossRef
121.
Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50:1344–1346CrossRef
122.
Emslie-Smith AM, Engel AG (1990) Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27:343–356PubMedCrossRef
123.
Kissel JT, Halyerman RK, Rammohan KW, Mendell JR (1991) The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 48:26–30PubMedCrossRef
124.
Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389–1401PubMedCrossRef
125.
Kaplan M (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3:1017–1023PubMed
126.
127.
Dalakas MC, Illa I, Gallardo E, Juarez C (1997) Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 41:100–104PubMedCrossRef
128.
Garlepp MJ, Mastaglia FL (2008) Inclusion body myositis: new insights into pathogenesis. Curr Opin Rheumatol 20:662–668PubMedCrossRef
129.
130.
Arahata K, Engel AG (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. 1. Quantification of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16:193–208PubMedCrossRef
131.
Lopez de Padilla CM, Vallajo AN, Lacomis D, McNallan K, Reed AM (2009) Extra-nodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60:1160–1172PubMedCrossRef
132.
Figarella-Branger D, Pellissier JF, Bianco N, Devictor B, Toga M (1990) Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cells and expression of the immunoglobulin class I major histocompatibility complex product. Acta Neuropathol (Berlin) 79:528–536CrossRef
133.
Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O’Connor KC, Amato AA (2005) Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65:1782–1787PubMedCrossRef
134.
De Bleecker JL, Engel AG, Butcher EC (1996) Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul Disord 6:255–260PubMedCrossRef
135.
Bradshaw EM, Orihuela A, McArdle SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O’Connor KC (2007) A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 178:547–556PubMed
136.
Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887–1896PubMedCrossRef
137.
Hengstman GJ, van Engelen BG, van Venrooij WJ (2004) Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 16:692–699PubMed
138.
Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48:607–612CrossRef
139.
Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey BK, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed
140.
Levine TD (2005) Rituximab in the treatment of dermatomyositis. An open-label pilot study. Arthritis Rheum 52:601–607PubMedCrossRef
141.
Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open label prospective study. J Rheumatol 34:1864–1868PubMed
142.
Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763–767PubMedCrossRef
143.
Sultan AM, Ng KP, Edwards JCW, Isenberg DA, Cambridge G (2008) Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26:887–893PubMed
144.
Sem M, Molberg O, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 48:968–971CrossRef
145.
Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62:1328–1334CrossRef
146.
Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50:2206–2213CrossRef
147.
Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol 38:1436–1440PubMedCrossRef
148.
Couderc M, Gottenberg JE, Mariette X, Hachulla E, Sibilia J, Fain O, Hot A, Dougados M, Euller-Ziegler L, Bourgeois P, Larroche C, Tournadre A, Amoura Z, Maziéres B, Arlet P, De Brandt M, Schaeverbeke T, Soubrier M (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 50:2283–2289PubMedCrossRef
149.
Garcîa-Hernåndez FJ, Gonzålez-Leon R, Castillo-Palma MJ, Sånchez-Romån J (2011) Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy. Clin Exp Rheumatol 29:363–364PubMed
150.
Garcîa Hernåndez FJ, Chinchilla Palomares E, Castillo Palma MJ, Gonzålez Pulido C, Ocaña Medina C, Sånchez Romån J (2010) Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy. Med Clin (Barcilona) 135:256–259CrossRef
151.
Oddis CV, Reed AM, Aggarwal R, Ascherman DP, Barohn RJ, Feldman BM, Koontz DC, Miller FW, Pryber SL, Rider LG, Rockette HE, The RIM group (2010) Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM): the RIM study (abstract). Arthritis Rheum 62:3844
152.
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM AM, Lachenbruch PA, Miller FW, International myositis assessment and clinical studies group (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:2281–2290PubMedCrossRef
153.
154.
Schmidt J, Dalakas MC (2010) Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapy. Exp Opin 4:241–250
155.
Orimo S, Koga R, Goto K, Nakamura K, Arai M, Tamaki M, Sugita H, Nonaka I, Arahata K (1994) Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord 4:219–226PubMedCrossRef
156.
Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R (1996) Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 97:2905–2910PubMedCrossRef
157.
Ikezoe K, Ohshima S, Osoegawa M, Tanaka M, Ogawa K, Nagata K, Kira JI (2006) Expression of granulysin in polymyositis and inclusion body myositis. J Neurol Neurosurg Psychiatry 77:1187–1190PubMedCrossRef
158.
Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L (1993) Analysis of T cell receptor repertoire in muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 91:2880–2886PubMedCrossRef
159.
O’Hanlon TP, Dalakas MC, Plotz PH, Miller FW (1994) Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 152:2569–2576PubMed
160.
Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R (1995) T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ cells. J Exp Med 181:1863–1868PubMedCrossRef
161.
Fyhr IM, Moslemi AR, Lindberg C, Oldfors A (1998) T cell receptor beta-chain repertoire in inclusion body myositis. J Neuroimmunol 91:129–134PubMedCrossRef
162.
Amemiya K, Granger RP, Dalakas MC (2000) Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123:2030–2039PubMedCrossRef
163.
Benveniste O, Herson S, Salomon B, Dimitri D, Trébeden-Négre H, Jean L, Bon-Durand V, Antonelli D, Klatzmann D, Boyer O (2004) Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 56:867–872PubMedCrossRef
164.
Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P (2003) Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of t cells in the pathogenesis of myositis. J Neuroimmunol 137:125–133PubMedCrossRef
165.
Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea AM, Tanaseanu C, Dumitrache S, Otelea D, Tamsulea I, Tanaseanu S, Chitonu C, Paraschiv S, Balteanu M, Stefanescu M, Matache C (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42:41–49PubMedCrossRef
166.
Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD (2009) Effect of alemtuzumab (Campath 1-H) in patients with inclusion-body myositis. Brain 132:1536–1544PubMedCrossRef
167.
168.
Dalakas MC, Rakocevic G, Schmidt J, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J (2010) Reply: comment on alemtuzumab and inclusion body myositis. Brain 133:e136CrossRef
169.
Cranmer LD, Hersh E (2007) The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 25:613–631PubMedCrossRef
170.
Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155:453–460PubMedCrossRef
171.
Nagaraju K, Raben N, Vllalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH (1999) Costimulatory markers in muscle of patients with idiopathic myopathies and in cultured muscle cells. Clin Immunol 92:161–169PubMedCrossRef
172.
173.
Lindvall B, Dahlbom K, Henriksson KG, Srinivas U, Ernerudh L (2003) The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ration in polymyositis. Acta Neurol Scand 107:134–141PubMedCrossRef
174.
Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, Marie SK (2006) Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 5:93–100PubMedCrossRef
175.
Tews DS, Goebel HH (1996) Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55:342–347PubMedCrossRef
176.
Cid MC, Grau JM, Casademont J, Tobias E, Picazo A, Coll-Vinent B, Esparza J, Pedrol E, Urbano-Mårquez A (1996) Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies. Clin Exp Immunol 104:467–473PubMed
177.
Jain A, Sharma MC, Sarkar MC, Bhatia R, Singh S, Handa R (2009) Increased expression of cell adhesion molecules in inflammatory myopathies: diagnostic utility and pathogenetic insights. Folia Neuropathol 47:33–42PubMed
178.
Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha 4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64:1336–1342PubMedCrossRef
179.
Steinman L (2006) Controlling autoimmunity in sporadic inclusion body myositis. Neurology 66(Suppl):S56–S58PubMedCrossRef
Metadata
Title
Targeted immunotherapy trials for idiopathic inflammatory myopathies
Author
Joerg-Patrick Stübgen
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 2/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6590-7

Other articles of this Issue 2/2013

Journal of Neurology 2/2013 Go to the issue

Original Communication

Seasonal and meteorological determinants of aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

Letter to the Editors

Crossed cerebellar hyperperfusion without restricted diffusion in status epilepticus

Medical Progress in the Journal of Neurology

Dementia and neuroimaging

Original Communication

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections

Letter to the Editors

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab

Original Communication

Treatment deviating from guidelines does not influence status epilepticus prognosis